Tag: indicators

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025.

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust ("CAPREIT") (TSX: CAR.UN) announced today its operating and financial results for the three and six months ended June 30, 2025. Management will host a conference call to discuss the financial results on Friday, August 8, 2025 at 9:00 a.m. ET.

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to report financial and operating results as at and for the three and six months ended June 30, 2025.

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust ("ERES" or the "REIT") (TSX: ERE.UN) announced today its results for the three and six months ended June 30, 2025.

CALGARY, Alberta, Aug. 06, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. ("NuVista" or the "Company") (TSX: NVA) is pleased to announce financial and operating results for the three and six months ended June 30, 2025, and to provide an update on our operational performance. We have continued to advance our business with the goal of creating top-tier returns for our shareholders. Our predictable and repeatable development plan continues to produce improved capital efficiencies, allowing us to reduce our capital expenditures guidance both this year and next and deliver average annual per share production growth of at least 15%. In the third quarter, we will be ramping up production toward 100,000 Boe/d and our 5-year outlook of growing production to 125,000 Boe/d remains fully in-tact and will be achieved with less capital than originally expected. With respect to returns to shareholders, we have directed over $100 million toward share repurchases in the first half of the year and continue to believe a balanced approach to absolute growth and share repurchases will drive superior total returns.

Q2 2025 Financial Highlights

ABN AMRO posts net profit of EUR 606 million in Q2 2025

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™.